1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. VentriPoint Diagnostics Ltd.
  6. News
  7. Summary
    VPT   CA92281P2008

VENTRIPOINT DIAGNOSTICS LTD.

(VPT)
Delayed Bourse de Toronto  -  05/13 03:52:56 pm EDT
0.2800 CAD   +3.70%
05/09Ventripoint Hires Two Strategic Sales Account Managers for US, Europe, and UK Distribution
AQ
05/03VentriPoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
05/03Ventripoint Announces Sponsorship for the 2022 SickKids Echo Symposium
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ventripoint Hires Iconic Investor Relations LLC to Provide Investor Relations Services

01/27/2022 | 08:51am EDT

(via TheNewswire)

Ventripoint Diagnostics Ltd.


Toronto, Ontario – TheNewswire – January 27, 2022- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT);(OTC:VPTDF) announcesit has entered into an investor relations agreement (the “IR Agreement”) with Iconic Investor Relations LLC (“Iconic”).  The IR Agreement is for a term of twelve months commencing on January 20, 2022.

 

With our recent uplisting to the OTCQB, we are looking forward to working with Iconic to inform shareholders and new investors in the United States about the Company’s progress to improve cardiac care worldwide,” stated Dr.George Adams, Executive-Chairman of Ventripoint.

 

John Grosso, President Iconic, stated: "We specialize in outreach to investors who are interested in companies with novel medical products, which will change healthcare in the United States and Ventripoint meets all our criteria with its disruptive technology to better visualize the heart using routine ultrasound exams.”

 

Pursuant to the IR Agreement, Iconic will be paid a fee of USD$10,000 per month and will be granted stock options to purchase 250,000 common shares of Ventripoint at a price of $0.33 per share for a term of two years vesting quarterly over 1 year, in accordance with the Ventripoint’s stock option plan.

 

The IR Agreement and grant of the options are subject to the approval of the TSX Venture Exchange.

About Ventripoint Diagnostics Ltd.

Ventripointhas become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

Forfurther information, please contact:

Peter Weichler, Investor Relations

Email: peter@weichler.ca

or

John Grosso, Iconic Investor Relations

Email:  john@iconiconsulting.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

ForwardLooking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR atwww.sedar.com.Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Copyright (c) 2022 TheNewswire - All rights reserved.

Copyright (c) 2022 TheNewswire - All rights reserved., source Press Releases

All news about VENTRIPOINT DIAGNOSTICS LTD.
05/09Ventripoint Hires Two Strategic Sales Account Managers for US, Europe, and UK Distribut..
AQ
05/03VentriPoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December ..
CI
05/03Ventripoint Announces Sponsorship for the 2022 SickKids Echo Symposium
AQ
04/27Ventripoint Welcomes Dr. Jose Banchs as New Clinical Advisor
AQ
04/19Ventripoint Welcomes Dr. Howard Michael Leong-Poi as New Clinical Advisor
AQ
04/18VENTRIPOINT DIAGNOSTICS LTD.(TSXV : VPT) dropped from S&P/TSX Venture Composite Index
CI
04/07Ventripoint Signs on AngioConsult/Angiopro as European Distributor
AQ
04/01Ventripoint to Exhibit at the American College of Cardiology 71st Annual Scientific Ses..
AQ
03/21Ventripoint Announces DTC Eligibility Approval in the U.S.
AQ
03/02Ventripoint Diagnostics Ltd. Hires Social Media Firm North Equities Corp
CI
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 43,6 M 33,7 M 33,7 M
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 95,3%
Chart VENTRIPOINT DIAGNOSTICS LTD.
Duration : Period :
VentriPoint Diagnostics Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Victor Johan Hugo Chief Financial Officer
George Adams Executive Chairman
Alvira Macanovic Vice President-Operations & Regulatory Affairs
Robert L. Hodgkinson Independent Director
Hugh MacNaught Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VENTRIPOINT DIAGNOSTICS LTD.-18.84%34
THERMO FISHER SCIENTIFIC-18.86%211 945
DANAHER CORPORATION-24.26%178 394
INTUITIVE SURGICAL, INC.-37.74%80 295
SIEMENS HEALTHINEERS AG-17.38%63 485
EDWARDS LIFESCIENCES CORPORATION-24.70%60 652